NEW YORK — Becton Dickinson said on Tuesday that it has acquired Cytognos, a privately held developer of flow cytometry-based tests for hematologic cancer and blood diseases, from its parent firm Vitros.
Financial and other terms of the deal were not disclosed. BD said that the acquisition would not be material to its fiscal 2022 financial results.
Based in Salamanca, Spain, Cytognos specializes in flow cytometry for blood cancer diagnosis, minimal residual disease detection, and immune monitoring research for blood diseases. The acquisition, Franklin Lakes, New Jersey-based BD said, will expand its portfolio of blood cancer diagnostics, immune assessment tests, and informatics aimed at chronic disease management.
"As the understanding and treatment of cancer evolves and improves, the importance of monitoring post remission cancer survivors has become paramount to improve patient outcomes," Puneet Sarin, worldwide president of BD Biosciences, said in a statement. "Cytognos' capabilities are complementary to those already developed by BD scientists to screen for the most common blood cancers and will enable BD to expand beyond cancer discovery and diagnosis into the monitoring phase of the patient's journey."
Through the transaction, BD also gains access to assays licensed to Cytognos by the EuroFlow Consortium, an independent network of European universities and hospitals specializing in hematology and immunology. BD said that it has an existing license agreement with EuroFlow for multiple other assays.
BD has completed 16 mergers and acquisitions since fiscal year 2020. At the 40th Annual JP Morgan Healthcare Conference last month, CEO Tom Polen said that the company expects to have capacity for up to $2 billion in tuck-in M&As per year going forward.